trending Market Intelligence /marketintelligence/en/news-insights/trending/Pu9gHuCdmr0wSxWleiSBSw2 content esgSubNav
In This List

Health Canada approves CSL unit's hemophilia A treatment

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Health Canada approves CSL unit's hemophilia A treatment

CSL Ltd. unit CSL Behring said Health Canada approved Afstyla for the treatment of hemophilia A.

Afstyla is a novel long-lasting recombinant factor VIII single-chain therapy for adults and children with the congenital bleeding disorder. The approval is based on the results of the Affinity clinical development program.

Afstyla is approved for use in the U.S. and Canada, and is being reviewed by regulators in global markets including the EU, Switzerland and Australia.